{
    "clinical_study": {
        "@rank": "17", 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the safety and effectiveness of giving HIV-infected\n      patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus\n      IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is\n      given in combination with other drugs."
        }, 
        "brief_title": "A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this multicenter, open-label study, 45 HIV-1-positive patients receive either combination\n      drug therapy with delavirdine (DLV), zidovudine (ZDV), and indinavir (IDV) or combination\n      drug therapy with ZDV, lamivudine (3TC), and IDV. NOTE: Patients are treated for 24 weeks\n      and may opt to continue on study for 24 additional weeks, if HIV-1 RNA is less than 5,000\n      copies/ml or at the investigator's discretion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV-1 positive.\n\n          -  CD4 count above 50.\n\n          -  HIV-1 RNA greater than 20,000.\n\n        Prior Medication:\n\n        Allowed:\n\n        Less than 1 month prior treatment with zidovudine.\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior 3TC, protease inhibitors, or non-nucleoside reverse transcriptase inhibitors.\n\n          -  Prior ZDV of greater than 1 month total duration.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Lamivudine.\n\n          -  Protease inhibitors.\n\n          -  Non-nucleoside reverse transcriptase inhibitors."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "45", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002400", 
            "org_study_id": "228C", 
            "secondary_id": "0063"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Delavirdine mesylate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Lamivudine", 
                "Reverse Transcriptase Inhibitors", 
                "Delavirdine", 
                "Indinavir", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Drug Therapy, Combination", 
            "Zidovudine", 
            "HIV Protease Inhibitors", 
            "Lamivudine", 
            "Indinavir", 
            "RNA, Viral", 
            "Delavirdine", 
            "Reverse Transcriptase Inhibitors"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Peapack", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07977"
                }, 
                "name": "Pharmacia & Upjohn"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open-Label Randomized Study of Delavirdine Mesylate (Rescriptor) in Combination With Zidovudine (Retrovir) and Two Doses of Indinavir (Crixivan) Versus Zidovudine, Lamivudine (Epivir), and Indinavir in HIV-1-Infected Individuals", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002400"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharmacia and Upjohn", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1999"
    }, 
    "geocoordinates": {
        "Pharmacia & Upjohn": "40.717 -74.657"
    }
}